A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD

Neurology

Volumn 54, Issue 8, 2000, Pages 1583-1588

  Schwid, Steven R ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

NMDA channel blocker; PD; Remacemide hydrochloride

Indexed keywords

REMACEMIDE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTIGO;

EID: 0342424715     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.8.1583     Document Type: Article

References (21)

1. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375.
2. Mitchell IJ, Clarke CE, Boyce S, et al. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 1989;32:213-226.
3. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990;249:1436-1438.
4. Porter RHP, Greene JG, Higgins DS, Greenamyre JT. Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activity in the basal ganglia of rats with unilateral dopamine depletion. J Neurosci 1994;14:7192-7199.
5. Greenamyre JT, Eller RV, Zhang Z, et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 1994;35:655-661.
6. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-578.
7. Blandini F, Porter RHP, Greenamyre JT. Glutamate and Parkinson's disease. Mol Neurobiol 1996;12:73-94.
8. Palmer GC, Murray RJ, Wilson TCM, et al. Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide. Epilepsy Res 1992;12:9-20.
9. Kieburtz K, Feigin A, McDermott M, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 1996;11:273-277.
10. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
11. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
12. Beck AT, Steer RA. Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol 1984;40: 1365-1367.
13. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of neurologic deficit. Boston: Butterworth, 1989:285-309.
14. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson MC, eds. Third Symposium on Parkinson's Disease. Edinburgh: Livingstone, 1969:152-157.
15. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991;114:2095-2122.
16. Arrowsmith JE, Harrison MJG, Newman SP, Stygall J, Timberlake N, Pugsley WB. Neuroprotection of the brain during cardiopulmonary bypass: a randomized trial of remacemide during coronary artery bypass in 171 patients. Stroke 1998;29:2357-2362.
17. Leach JP, Blacklaw J, Jamieson V, Jones T, Richens A, Brodie MJ. Mutual interactions between remacemide hydrochloride and carbamazepine: two drugs with active metabolites. Epilepsia 1996;37:1100-1106.
18. Leach JP, Girvan J, Jamieson V, Jones T, Richens A, Brodie MJ. Mutual interaction between remacemide and phenytoin. Epilepsy Res 1997;26:381-388.
19. Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine, and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res 1995;20:250-267.
20. Klockgether T, Turski L. NMDA antagonists potentiate anti-parkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 1990;28:539-546.
21. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998;44:S175-S188.